PAX5 and nonpapillary renal cell carcinoma: In our study, we demonstrated that PAX5 can promote the synthesis of circSOD2 and thus promote the development of RCC, which further supports that circSOD2 may be a biomarker for risk stratification and prognostic prediction in ccRCC patients.